KGC Insam Gongsa Signs MOU with International Vaccine Institute

Supply of 12 Types of Ginsenoside in Jeonggwanjang Red Ginseng, Development of Immune Enhancers Needed for Vaccine Research
Utilization of Immune Enhancer Development from Red Ginseng Components through Joint Research with International Vaccine Institute

Jerome Kim, Secretary-General of the International Vaccine Institute (IVI) (left), and Kim Jae-su, President of KGC Ginseng Corporation, are posing for a commemorative photo after exchanging a memorandum of understanding.

[Asia Economy Reporter Lee Seon-ae] KGC Ginseng Corporation signed a memorandum of understanding (MOU) on the 3rd to cooperate with the International Vaccine Institute in the development of immune adjuvants.

The signing ceremony took place at the International Vaccine Institute located at Seoul National University, attended by Director-General Jerome Kim, KGC Ginseng Corporation President Kim Jae-su, and R&D Director Park Chae-gyu, among others.

KGC Ginseng Corporation and the International Vaccine Institute plan to collaborate on developing immune adjuvants necessary for vaccine research using CheongKwanJang Red Ginseng. Immune adjuvants are substances that enhance the immune response triggered by antigens; when included in vaccines, they can achieve the same efficacy with a smaller amount of antigen, making them very important in vaccine development.

Through this MOU, KGC Ginseng Corporation will supply 12 types of ginsenosides contained in CheongKwanJang Red Ginseng, and the International Vaccine Institute will study the effects of ginsenosides as immune adjuvants, expecting to contribute to vaccine development.

Red ginseng is a health functional food recognized by the Ministry of Food and Drug Safety for its ability to increase immune cells or regulate their functions, thereby helping to boost immunity.

Dr. Song Manki, Scientific Deputy Director of the International Vaccine Institute, stated, “As part of various strategies to develop immune adjuvants needed for vaccines against COVID-19 and other diseases, we will study the immune adjuvant effects of red ginseng.”

Park Chae-gyu, R&D Director of KGC Ginseng Corporation, said, “We expect that utilizing CheongKwanJang Red Ginseng components in vaccines through this MOU will further enhance the value of red ginseng.”

Meanwhile, the International Vaccine Institute is a nonprofit international organization dedicated to vaccine research, development, and distribution, and is currently collaborating with domestic and international vaccine developers to develop COVID-19 vaccines in response to the global pandemic.

This content was produced with the assistance of AI translation services.